Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2012 09:51 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa(TM) in the Middle East and the Gulf

SAN DIEGO and DUBAI, United Arab Emirates, Jan. 10, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (www.apricusbio.com) (Nasdaq:APRI) and Elis Pharmaceuticals ("Elis")...
January 09, 2012 16:14 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to Webcast Today's Presentation at Biotech Showcase(TM) 2012 in San Francisco

SAN DIEGO, Jan. 9, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Chairman, President and Chief Executive Officer,...
January 09, 2012 12:28 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences and Abbott Sign Exclusive Agreement to Market Vitaros(R) (Alprostadil) in Canada

SAN DIEGO, Jan. 9, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that it has entered into an exclusive licensing...
January 04, 2012 09:49 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences CEO, Dr. Bassam Damaj, to Present at Biotech Showcase(TM) 2012 in San Francisco

SAN DIEGO, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Dr. Bassam Damaj, Chairman, President and Chief...
January 03, 2012 09:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis

Apricus Bio Can Receive Up to Approximately $8 Million (Canadian) Plus Tiered Double Digit Royalties Under Multi-year Agreement Stellar Pharma Strengthens Its Dermatology Business in Canada With...
December 29, 2011 12:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Completes Acquisition of Topotarget USA, Inc.

SAN DIEGO, Dec. 29, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today the closing of its acquisition of Topotarget USA, Inc.,...
December 16, 2011 08:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Launches Commercialization Arm With Definitive Agreement to Acquire Topotarget USA

SAN DIEGO, Dec. 16, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today a definitive agreement to acquire Topotarget USA, Inc....
December 15, 2011 10:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Oral Presentation of Efficacy and Clinical Safety Data for Vitaros(R) and Femprox(R) at the African Society for Sexual Medicine Conference

SAN DIEGO, Dec. 15, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today the planned, oral presentation of clinical efficacy and safety...
December 12, 2011 11:46 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences' Vitaros(R) Podium Presentation Named Best Clinical Presentation 2011 (Male Sexual Disorder) by the Scientific Committee of the Congress for the European Society of Sexual Medicine Meeting in Milan

SAN DIEGO, Dec. 12, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today that its podium presentation by Dr. Jacques Buvat on...
December 08, 2011 10:01 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Allowance of Additional NexACT(R) Patent in Japan

SAN DIEGO, Dec. 8, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today that the Japanese Patent Office has issued an official decision to...